can semaglutide cause autoimmune disease GLP-1 Drugs Lower Risk of Death by 44% in Obesity and GLP-1 Side Effects and Semaglutide:

Mounjaros prescribing information states that use has been associated with gastrointestinal adverse reactions, sometimes severe, and that Mounjaro is not recommended in patients with severe gastroparesis

What the medical community says The medical community is divided on semaglutide split dosing, which reflects the current state of evidence rather than any fundamental disagreement about the pharmacology

Ready to start your weight loss journey today

The FDA added it to injectable semaglutide in January 2025, and it climbs the dose axis like everything else. Burning or tingling skin tracks the dose, not the weight lost, and an active-comparator study put the risk about twice that of another weight-loss drug. The mechanism is unsettled: the tempting "it is the drugs signaling arm" story is ruled out, because the strongest GLP-1 signaler in the class carries no such signal